Results 101 to 110 of about 18,928 (205)

Prognostic Implication of CYP2C19 Genotype According to Clinical Risk Stratification After Drug‐Eluting Stent Implantation

Clinical Pharmacology &Therapeutics, Volume 119, Issue 4, Page 928-941, April 2026.
From the nationwide multicenter consortium, 8,163 patients undergoing drug‐eluting stent implantation were classified according to the presence of the CYP2C19 loss‐of‐function (LoF) allele: rapid or normal metabolizers (RMs/NMs) vs. intermediate or poor metabolizers (IMs/PMs), and clinical risk was stratified using the CHADS‐P2A2RC and TRS 2°P scores ...
Hyun Woong Park, Jae‐Hwan Lee, Jin‐Ok Jeong, Diana A. Gorog, Udaya S. Tantry, Byeong‐Keuk Kim, Hyung Joon Joo, Kiyuk Chang, Jin‐Yong Hwang, Young Bin Song, Sung Gyun Ahn, Jung‐Won Suh, Woong Gil Choi, Jung Rae Cho, Jeehoon Kang, Sang Yeub Lee, Hyo‐Soo Kim, Moo Hyun Kim, Do‐Sun Lim, Eun‐Seok Shin, Paul A. Gurbel, Young‐Hoon Jeong, on behalf of the PTRG‐DES Consortium Investigators   +22 more
wiley   +1 more source

Place of Prasugrel, P2Y12 receptor antagonist, in an early invasive treatment of patients with acute coronary syndrome (according to the results of multicenter randomized controlled trial ISAR-REACT 5)

Российский кардиологический журнал, 2019
The conclusion of the Expert Council reports an agreement on the place of the P2Y12 receptor blocker prasugrel in the early invasive treatment of patients with acute coronary syndrome ACS, according to the results of the multicenter randomized controlled
S. N. Tereshchenko, M. G. Glezer, S. A. Abugov, O. V. Averkov, S. I. Antipov, A. S. Galyavich, M. Yu. Gilyarov, D. V. Duplyakov, A. A. Efremushkina, D. A. Zateyshchikov, V. V. Ivanenko, E. D. Kosmacheva, O. V. Krestyaninov, Yu. M. Lopatin, E. P. Panchenko, V. V. Ryabov, E. V. Samokhvalov, I. I. Staroverov, S. A. Ustyugov, A. V. Khripun, S. V. Shalaev, R. M. Shakhnovich, I. S. Yavelov, A. N. Yakovlev, S. S. Yakushin   +24 more
doaj   +1 more source

Consolidation of P2Y12 Testing While Maintaining Quality and Turnaround Time [PDF]

, 2017
Objective: To consolidate the test performed at 2 different locations at 1, thereby improving cost effectiveness while maintaining quality and result turnaround time.https://jdc.jefferson.edu/patientsafetyposters/1059/thumbnail ...
Gong, MD, Jerald Z., Jagannathan, MBBS, Geetha   +1 more
core   +1 more source

Cangrelor for the management and prevention of arterial thrombosis [PDF]

, 2016
INTRODUCTION: Despite advances in antiplatelet therapy, the optimum antithrombotic regimen during percutaneous coronary intervention (PCI) remains to be determined.
Sinha, A., Storey, R.F.
core   +1 more source

Comparison of P2Y12 inhibitors for mortality and stent thrombosis in patients with acute coronary syndromes: Single center study of 10 793 consecutive ‘real-world’ patients

Platelets, 2017
Three oral platelet P2Y12 inhibitors, clopidogrel, prasugrel, and ticagrelor, are available for reducing the risk of cardiovascular death and stent thrombosis in patients with acute coronary syndromes (ACS).
Rebecca Gosling, Momina Yazdani, Yasir Parviz, Ian R Hall, Ever D. Grech, Julian P Gunn, Robert F. Storey, Javaid Iqbal   +7 more
doaj   +1 more source

Quality indicators for acute myocardial infarction : a position paper of the Acute Cardiovascular Care Association [PDF]

, 2016
Evaluation of quality of care is an integral part of modern healthcare, and has become an indispensable tool for health authorities, the public, the press and patients.
Bonnefoy, Eric, Botker, Hans E., Bueno, Hector, Capuano, Frederic, Claeys, Marc J., Danchin, Nicolas, Fox, Keith A. A., Gale, Chris P., Huber, Kurt, Iakobishvili, Zaza, Lettino, Maddalena, Quinn, Tom, Rubini Gimenez, Maria, Schiele, Francois, Swahn, Eva, Timmis, Adam, Tubaro, Marco, Vrints, Christiaan, Walker, David, Zahger, Doron, Zeymer, Uwe   +20 more
core   +1 more source

Duration of dual antiplatelet therapy in acute coronary syndrome [PDF]

, 2017
Despite a large volume of evidence supporting the use of dual antiplatelet therapy in patients with acute coronary syndrome, there remains major uncertainty regarding the optimal duration of therapy.
Baber, Bhatt, Bittl, Bonaca, Breet, Budaj, Cairns, Cairns, Chen, Collet, Colombo, Eisenstein, Farooq, Feres, Fox, Gilard, Gurbel, Gwon, Généreux, Hamid, Karrowni, Kerneis, Kim, Lee, Levine, Lewis, Lewis, Martínez-Sales, Mauri, Mehta, Members, Navarese, O'Donoghue, Palmerini, Pfisterer, Price, Rao, Roffi, Sabatine, Schulz-Schüpke, Steg, Stone, Stone, The RISC Group, Trip, Udell, Valgimigli, Valgimigli, Wallentin, White, Wiviott, Yeh, Yusuf, Yusuf   +53 more
core   +7 more sources

Adjunctive therapies to reduce thrombotic events in patients with a history of myocardial infarction : role of vorapaxar [PDF]

, 2015
© 2015 Farag et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) LicenseAcute myocardial infarction (AMI) is generally attributed to coronary atherothrombotic ...
Farag, Mohamed, Gorog, Diana A, Patel, Hiten   +2 more
core   +3 more sources

Comparison of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention

Vascular Health and Risk Management, 2009
Nicholas B Norgard,1 Mazen Abu-Fadel21University at Buffalo, School of Pharmacy and Pharmaceutical Sciences, Buffalo, NY, USA; 2University of Oklahoma Health Sciences Center, Cardiovascular Section, Oklahoma City, OK, USAAbstract: Antiplatelet agents are
Nicholas B Norgard, Mazen Abu-Fadel
doaj  

Prasugrel Results in Higher Decrease in High-Sensitivity C-Reactive Protein Level in Patients Undergoing Percutaneous Coronary Intervention Comparing to Clopidogrel

Clinical Medicine Insights: Cardiology, 2016
Objectives A growing body of clinical and laboratory evidence indicates that inflammation plays a crucial role in atherosclerosis. In the present study, we compared the effects of clopidogrel and prasugrel on high-sensitivity C-reactive protein (hs-CRP ...
Shokoufeh Hajsadeghi, Mandana Chitsazan, Mitra Chitsazan, Negar Salehi, Ahmad Amin, Arash Amin Bidokhti, Nima Babaali, Armin Bordbar, Maral Hejrati, Samar Moghadami   +9 more
doaj   +1 more source